Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2347${count})

  • Research Grant Supplement, 2012
    Generation and Characterization of iPS Neurons from Genetic Parkinson’s Disease

     

    Promising Outcomes of Original Grant:
    The goal of the previous project was to establish iPS-derived neurons from patients with PINK1- and Parkin-linked familial forms of PD.  We used the latest...

  • Clinical Intervention Awards, 2012
    A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson’s Disease
    Objective/Rationale: In the twenty-first century the motor symptoms of Parkinson’s disease (PD) are typically well-managed. The neurocognitive symptoms of Parkinson’s disease often result in...
  • Therapeutics Development Initiative, 2012
    Lead Optimization for a Parkinson's Disease Therapeutic

    Objective/Rationale: 
    CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve...

  • Target Validation, 2012
    DLN-101 for the Treatment of Parkinson’s Disease
    Objective/Rationale: Dln101 is a novel protein from the ghrelin family. Dln101 has several clinical and commercial advantages over ghrelin, which make it a more attractive drug target. In previous...
  • Novel Approaches to Drug Discovery, 2012
    Optimizing Metalloporphryins for Clinical Development Supplement 2

    Promising Outcomes of Original Grant:
    A newly developed glyoxylate series of metalloporphyrin compounds designed to penetrate the blood brain barrier have shown high potencies as antioxidants. A recent...

  • Repositioning Drugs for PD, 2012
    Improving Levodopa Bioavailability and Consistency of Absorption through Co-administration of GSK962040

    Objective/Rationale:
    Parkinson’s disease (PD) often results in slower than normal emptying of food and medications from the stomach. This delayed gastric emptying is estimated to affect 50-90 percent...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.